NCT02553889View on ClinicalTrials.gov

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
End-stage Renal Disease (ESRD)
Interventions
DRUG

ISIS 416858

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Trial Locations (8)

T6G 2P4

Ionis Investigative Site, Edmonton

B3H 1V8

Ionis Investigative Site, Halifax

L8N 4A6

Ionis Investigative Site, Hamilton

N6A 5W9

Ionis Investigative Site, London

M5B 1W8

Ionis Investigative Site, Toronto

M9N 1N8

Ionis Investigative Site, Toronto

H2X 0A9

Ionis Investigative Site, Montreal

H4J 1C5

Ionis Investigative Site, Montreal

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY